Exposure-toxicity relationships for tipifarnib in cancer patients.

Exposure-toxicity relationships for tipifarnib in cancer patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Exposure-toxicity relationships for tipifarnib in cancer patients. Abstract Text:

Juan Jose Perez-Ruixo,Wei Chen,Steven Zhang,Siobhan Hayes,Andrew Chow,Juan Jose Perez-Ruixo,Wei Chen,Steven Zhang,Siobhan Hayes,Andrew Chow,

AIMS: To explore the potential relationship between systemic exposure to tipifarnib and the incidence of toxicity in cancer patients. METHODS: Data from 673 subjects (540 receiving tipifarnib and 133 receiving placebo) were included in the analysis. Tipifarnib was administered in doses ranging from 100 mg to 850 mg twice daily under fed conditions for 21 days in a 28 day cycle. Univariate and multivariate logistic regression models were used to evaluate the relationships between tipifarnib exposure and haematological (neutropenia and thrombocytopenia) and nonhaematological toxicities. Tipifarnib exposure was quantified as the area under the curve during the first cycle of chemotherapy (AUC), the maximum plasma concentration (C(max)), the time above plasma tipifarnib concentrations of 400 (T400) and 600 ng ml(-1) (T600), the cumulative area under the curve (AUC(T)), and the area under the curve density (AUC(D)), defined as the ratio AUC(T) to the duration of treatment. The nonhaematological toxicities measured were elevation of AST, ALT, bilirubin and serum creatinine, the occurrence of a skin rash, CNS or peripheral neuropathy, nausea and vomiting, diarrhoea and inflammation of the gastrointestinal tract. Odds ratios (OR) associated with drug exposure were used to measure the effect of the drug. RESULTS: Tipifarnib AUC exhibited a positive and significant association with neutropenia grade > or =3 (OR 1.69, 95% CI 1.47, 1.95) and thrombocytopenia grade > or =3 (OR 1.41, 95% CI 1.21, 1.63) in patients with solid tumours, but not in refractory or relapsed AML patients. The incidence of exposure-related nonhaematological toxicity is small regardless of tumour type. No association was found between tipifarnib AUC and the elevation of AST, ALT and total bilirubin, and nausea and vomiting. There was a weak relationship between tipifarnib AUC and serum creatinine elevation (OR 1.18, 95% CI 1.11, 1.26), CNS (OR 1.05, 95% CI 1.01, 1.10) and peripheral neurotoxicity (OR 1.10, 95% CI 1.03, 1.18), diarrhoea (OR 1.14, 95% CI 1.08, 1.21), gastrointestinal tract inflammation (OR 1.13, 95% CI 1.07, 1.19), and skin rash (OR 1.10, 95% CI 1.04, 1.17). CONCLUSIONS: In those patients who develop severe toxicity, dose reduction may improve the tolerability of tipifarnib. However, an exposure-guided approach to dosage adjustment to limit haematological and nonhaematological toxicity is not warranted.

Exposure-toxicity relationships for tipifarnib in cancer patients. Publishing Authors By Initials

JJ Perez-Ruixo,W Chen,S Zhang,S Hayes,A Chow,JJ Perez-Ruixo,W Chen,S Zhang,S Hayes,A Chow,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Exposure-toxicity relationships for tipifarnib in cancer patients. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: British journal of clinical pharmacology

VOLUME: 64

Page Numbers: 219-32

Journal Abbreviation:

ISSN: 0306-5251

DAY: 22

MONTH: 03

YEAR: 2007

Exposure-toxicity relationships for tipifarnib in cancer patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7503323

Exposure-toxicity relationships for tipifarnib in cancer patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Exposure-toxicity relationships for tipifarnib in cancer patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Exposure-toxicity relationships for tipifarnib in cancer patients.

AFFILIATION: Clinical Pharmacology Division, Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium. jperezru@prdbe.jnj.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Clin Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Exposure-toxicity relationships for tipifarnib in cancer patients Related Publications

• A high-throughput method for cloning and sequencing human immunodeficiency virus type 1 integration sites.
• A multidisciplinary bone metastases clinic at toronto sunnybrook regional cancer centre - a review of the experience from 1999 to 2005.
• Clinical use of clopidogrel in acute coronary syndrome.
• Continuous ambulatory peritoneal dialysis is better than automated peritoneal dialysis as first-line treatment in renal replacement therapy.
• Correcting the anion gap for hypoalbuminaemia does not improve detection of hyperlactataemia.
• Effects of calcium phosphate nanoparticles on Ca-PO4 composite.
• Fast setting calcium phosphate cement-chitosan composite: mechanical properties and dissolution rates.
• Gram-negative peritonitis--the Achilles heel of peritoneal dialysis?
• MalE of group A Streptococcus participates in the rapid transport of maltotriose and longer maltodextrins.
• Maximizing the success of peritoneal dialysis in high transporters.
• Mechanisms of peptide hormone secretion.
• Mitogen-activated protein kinases activate the nuclear localization sequence of human papillomavirus type 11 E1 DNA helicase to promote efficient nuclear import.
• Non-infectious aortitis: an important cause of severe aortic regurgitation.
• Occupation and adult-onset asthma among Chinese women in a population-based cohort.
• Percutaneous cementoplasty of lytic metastasis in left acetabulum.
• Photochemical hydroxylation of phenylephrine to epinephrine (adrenaline).
• Premixed calcium phosphate cements: synthesis, physical properties, and cell cytotoxicity.
• Probing RNA hairpins with cobalt(III)hexammine and electrospray ionization mass spectrometry.
• Quantification of a cytochrome P450 3A4 substrate, buspirone, in human plasma by liquid chromatography-tandem mass spectrometry.
• Review of the Rapid Response Radiotherapy Program (RRRP) at the Toronto Sunnybrook Regional Cancer Centre (TSRCC).
• Role of Ca2+-activated K+ channels in duodenal mucosal ion transport and bicarbonate secretion.
• Shoulder External Rotation Passive Flexibility is Altered by Increased Repetitions in Tennis Players: 2540: Board #87 June 2 8:00 AM - 9:30 AM.
• Solitary bone metastasis beneath the shoulder shield: coincidence or cause?
• Sonographic findings of ovarian torsion in children.
• Studies of chemical components of Angora goat seminal plasma.
• The do-not-resuscitate order: incidence of documentation in the medical records of cancer patients referred for palliative radiotherapy.
• Thermodynamic investigation of the role of contact residues of beta-lactamase-inhibitory protein for binding to TEM-1 beta-lactamase.
• [A brief history of the early stage of malaria control in China]
• [Effectiveness and safety of intragastric balloon for treatment of morbid obesity]
• [Study of FTIR spectra and thermal analysis of polyurethane]